Gerald S. Falchook

机构：Sarah Cannon Research Institute, Sarah Cannon, HealthONE, Tennessee Oncology · ORCID：0000-0001-9165-2191

发表论文 813 篇 · 总被引 27975 次 · h-index 69

代表论文

• First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation (2025 · Journal of Clinical Oncology · 被引 11)
• Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial (2026 · The Lancet Oncology · 被引 5)
• Phase I Trial of P-PSMA-101 CAR T Cells in Patients with Metastatic Castration-Resistant Prostate Cancer (2026 · Clinical Cancer Research · 被引 4)
• A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors (2026 · npj Precision Oncology · 被引 2)
• Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer (2026 · British Journal of Cancer · 被引 1)
• 615 Phase 1 study of intratumoral VAX014 with dose expansion in combination with pembrolizumab or nivolumab in patients with advanced solid tumors (2025 · Regular and Young Investigator Award Abstracts · 被引 1)